Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
about
Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies.Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Urinary biomarkers in lupus nephritis.Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus.Kidney transplantation in patients with systemic lupus erythematosus.Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United StatesRacial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus NephritisCross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritisAmerican College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisTreatment for lupus nephritis: an overview of systematic reviews and meta-analyses.Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus RegistryIncidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus RegistryUrinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis.Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.Disparities in lupus care and outcomes.Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery StudyRecent progress in the treatment of lupus nephritis.Immunomodulators in SLE: Clinical evidence and immunologic actions.Why targeted therapies are necessary for systemic lupus erythematosus.Regulatory T cells in Acute and Chronic Kidney Diseases.Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.Predictors of incident proteinuria among patients with SLE.After 4 Decades of Lupus Nephritis Trials, Is There a "Best" Therapy?Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.
P2860
Q31125878-5D23AE27-795A-4A45-A830-98E9F4983839Q33698040-2E28FA3B-2AD2-4E6D-8B67-379D7D9699D8Q34050022-D9E9B0DC-4A57-44B1-9E45-C8BEA18BF68FQ34187295-869B8F3C-BEB2-4EDA-BABB-9029B01D0392Q34397379-D9CCF46D-91D4-47EE-B52F-4659BC3D2401Q35019423-F6B7F914-B9F9-4382-806B-A4F9F4792011Q35583267-4BB91875-3A9D-49AD-A9A2-A480B2A596C0Q35890096-9E03501F-712A-4C3C-BA02-C00C5F3C5A3CQ36083938-9175907E-BD7B-4068-9E82-F1F227EE880FQ36221407-0E9CA9F0-92D0-4F99-91F2-7A069897274EQ36368688-06F083C1-B011-4424-A7FC-991CA0FB532DQ36517240-7F0B0A65-3A35-432C-8D0A-35587AB6CDD9Q36540787-1F50EB69-7861-49BA-9516-FEE51168EE41Q36713542-2BF0EB4E-AB39-4C85-A6A4-9A91C463304BQ37185798-DC10DA1B-9083-465D-A5FA-933D3FCED6A7Q37413878-7DD345D4-3788-4FF1-A47D-4D8B7EF8AF0BQ37541229-866A3678-F8F7-43E8-83FB-A145AA1C35B1Q38010014-B72A6561-8E14-4C89-A81B-0104C45FC352Q38883883-31DA669D-2610-4207-B550-9795892D5736Q38920435-02A041AA-E9C9-4737-81A1-E0E6981BF9B0Q45066685-1FB0393B-B4F7-40AA-AB97-23F427C9EBABQ46769274-C2ECCFB1-EB9C-4E9E-A038-E20C09B88A57Q47100353-B2A2DD52-7373-48BF-A93E-11CE2130CC17Q53096167-2AB4A9D5-1C48-45DB-86B9-EECE1EDAD600Q54679503-C94B88A6-23C5-42A8-A7D5-FD2E84511AE5
P2860
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
@ast
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
@en
type
label
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
@ast
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
@en
prefLabel
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
@ast
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
@en
P1476
Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.
@en
P2093
P304
P356
10.1001/ARCHINTE.160.20.3136
P407
P577
2000-11-01T00:00:00Z